Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
MacLeod S, Musich S, Keown K, Yeh CS. Practical technological solutions to support successful aging. J Aging Geriatr Med. 2019 Aug 14;3(1).
MacLeod S, Musich S, Ruiz JM, Yeh CS. Perceptions of aging and their impact on older adults' health outcomes. J Aging Geriatr Med. 2019 Apr 30;3(1).
MacLeod S, Musich S, Parikh RB, Hawkins K, Keown K, Yeh CS. Examining approaches to address loneliness and social isolation among older adults. J Aging Geriatr Med. 2018 Feb 8;2(1). doi: 10.4172/2576-3946.1000115
Layton JB, Sturmer T, Brookhart MA. Misinterpretation of the comparative safety of testosterone dosage forms - Reply. JAMA Intern Med. 2015 Nov;175(11):1875-6. doi: 10.1001/jamainternmed.2015.5807
Layton JB, Meier CR, Sharpless JL, Sturmer T, Jick SS, Brookhart MA. Comparative safety of testosterone dosage forms. JAMA Intern Med. 2015 Jul;175(7):1187-96. doi: 10.1001/jamainternmed.2015.1573